StockNews.com Begins Coverage on Atrion (NASDAQ:ATRI)

StockNews.com assumed coverage on shares of Atrion (NASDAQ:ATRIFree Report) in a research note published on Sunday morning. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Stock Performance

Shares of ATRI opened at $459.92 on Friday. Atrion has a fifty-two week low of $274.98 and a fifty-two week high of $503.24. The company has a market capitalization of $809.46 million, a price-to-earnings ratio of 43.23 and a beta of 0.69. The firm has a 50-day simple moving average of $455.98 and a 200-day simple moving average of $429.96.

Atrion (NASDAQ:ATRIGet Free Report) last announced its earnings results on Thursday, August 8th. The medical instruments supplier reported $0.23 earnings per share for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The business had revenue of $48.77 million during the quarter.

Institutional Investors Weigh In On Atrion

A number of hedge funds have recently added to or reduced their stakes in ATRI. Quadrant Capital Group LLC acquired a new stake in Atrion in the fourth quarter valued at about $36,000. Headlands Technologies LLC acquired a new stake in Atrion in the second quarter valued at about $54,000. Benjamin F. Edwards & Company Inc. acquired a new stake in Atrion in the second quarter valued at about $72,000. EntryPoint Capital LLC acquired a new stake in Atrion in the first quarter valued at about $91,000. Finally, Comerica Bank lifted its position in Atrion by 60.9% in the first quarter. Comerica Bank now owns 415 shares of the medical instruments supplier’s stock valued at $192,000 after purchasing an additional 157 shares during the period. Institutional investors and hedge funds own 66.19% of the company’s stock.

About Atrion

(Get Free Report)

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.

Read More

Receive News & Ratings for Atrion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atrion and related companies with MarketBeat.com's FREE daily email newsletter.